AR055723A1 - Uso del farmaco analgesico no opiaceo flupirtina para el tratamiento de vejiga hiperactiva y enfermedades asociadas, que incluyen incontinencia por urgencia, problemas de flujo urinario como consecuencia de hiperplasia de prostata y sindrome de intestino irritable - Google Patents

Uso del farmaco analgesico no opiaceo flupirtina para el tratamiento de vejiga hiperactiva y enfermedades asociadas, que incluyen incontinencia por urgencia, problemas de flujo urinario como consecuencia de hiperplasia de prostata y sindrome de intestino irritable

Info

Publication number
AR055723A1
AR055723A1 ARP060100341A ARP060100341A AR055723A1 AR 055723 A1 AR055723 A1 AR 055723A1 AR P060100341 A ARP060100341 A AR P060100341A AR P060100341 A ARP060100341 A AR P060100341A AR 055723 A1 AR055723 A1 AR 055723A1
Authority
AR
Argentina
Prior art keywords
treatment
hyperplasia
flupirtine
irestriable
pharmaco
Prior art date
Application number
ARP060100341A
Other languages
English (en)
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of AR055723A1 publication Critical patent/AR055723A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Prevencion, reversion y tratamiento médico de disfuncion del tracto urinario que incluye inestabilidad de vejiga y otras enfermedades relacionadas, que incluye problemas de flujo urinario, urgencia e incontinencia como consecuencia de hiperplasia de prostata (BPH) y para la prevencion, la reversion y el tratamiento médico del síndrome de intestino irritable (IBS) con especial atencion en el IBS a predominio de diarrea y de tipo mixto con diarrea y constipacion, tanto en humanos como en animales. Reivindicacion 1: Uso de flupirtina o uno de sus derivados farmacologicamente aceptables como agente activo para la fabricacion de un medicamento para el tratamiento, la inhibicion o la prevencion de la disfuncion del tracto urinario inferior o un síndrome de intestino irritable en un mamífero.
ARP060100341A 2005-01-31 2006-01-30 Uso del farmaco analgesico no opiaceo flupirtina para el tratamiento de vejiga hiperactiva y enfermedades asociadas, que incluyen incontinencia por urgencia, problemas de flujo urinario como consecuencia de hiperplasia de prostata y sindrome de intestino irritable AR055723A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05001967A EP1688141A1 (en) 2005-01-31 2005-01-31 The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome

Publications (1)

Publication Number Publication Date
AR055723A1 true AR055723A1 (es) 2007-09-05

Family

ID=34933533

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100341A AR055723A1 (es) 2005-01-31 2006-01-30 Uso del farmaco analgesico no opiaceo flupirtina para el tratamiento de vejiga hiperactiva y enfermedades asociadas, que incluyen incontinencia por urgencia, problemas de flujo urinario como consecuencia de hiperplasia de prostata y sindrome de intestino irritable

Country Status (14)

Country Link
US (1) US7309713B2 (es)
EP (2) EP1688141A1 (es)
KR (1) KR20070102726A (es)
CN (1) CN101132793A (es)
AR (1) AR055723A1 (es)
AU (1) AU2006208618A1 (es)
BR (1) BRPI0606897A2 (es)
CA (1) CA2596619A1 (es)
IL (1) IL183557A0 (es)
MX (1) MX2007009187A (es)
NO (1) NO20074453L (es)
RU (1) RU2007132725A (es)
TW (1) TW200637548A (es)
WO (1) WO2006079559A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
AU2007288253B2 (en) * 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
KR20090083479A (ko) * 2006-11-28 2009-08-03 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
PL3409274T3 (pl) * 2008-12-22 2020-06-01 Novartis Ag Schemat dawkowania dla agonisty receptora s1p
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
CN109053562B (zh) * 2018-07-20 2022-05-27 四川青木制药有限公司 一种制备a晶型高堆密度的马来酸氟吡汀的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670523A1 (de) * 1966-05-12 1970-12-03 Degussa Verfahren zur Herstellung neuer substituierter Aminopyridine
DE1670255A1 (de) * 1967-08-02 1971-01-28 Basf Ag Verfahren zur Herstellung von 2-Aryl-3-amino-indazolen
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
DE3663775D1 (en) * 1985-02-23 1989-07-13 Asta Pharma Ag Combination of flupirtin with spasmolytics having an anticholinergic effect
DE3604575A1 (de) * 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
IN172468B (es) * 1990-07-14 1993-08-14 Asta Medica Ag
GB9220570D0 (en) 1991-10-21 1992-11-11 Ici Plc Therapeutic agent
ATE160696T1 (de) * 1992-03-11 1997-12-15 Asta Medica Ag Tabletten, granulate und pellets mit hohem gehalt an wirkstoffen für hochkonzentrierte, feste darreichungsformen
DE4236752A1 (de) 1992-10-30 1994-05-05 Asta Medica Ag Kombinationspräparat aus Flupirtin und Morphin zur Behandlung von Schmerzen und zur Vermeidung der Morphin-Abhängigkeit
DE4319649A1 (de) 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
DE19625582A1 (de) 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
DE19934523A1 (de) * 1999-07-22 2001-01-25 Novosis Pharma Ag Transdermalsysteme zur Abgabe von Muscarin-Rezeptor-Antagonisten und ihre Verwendung zur Behandlung von Spasmen der glatten Muskulatur im urologischen Bereich
AU1353901A (en) 1999-12-01 2001-06-12 Duke University Method of treating batten disease
US6412554B1 (en) * 2000-03-14 2002-07-02 Weatherford/Lamb, Inc. Wellbore circulation system
MXPA03000032A (es) 2000-06-29 2003-08-19 Neurosearch As Uso de derivados de oxindol 3-sustituidos como moduladores de los canales de potasio kcnq.
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function

Also Published As

Publication number Publication date
CA2596619A1 (en) 2006-08-03
AU2006208618A1 (en) 2006-08-03
KR20070102726A (ko) 2007-10-19
US20060173052A1 (en) 2006-08-03
NO20074453L (no) 2007-10-18
EP1688141A1 (en) 2006-08-09
WO2006079559A2 (en) 2006-08-03
WO2006079559A3 (en) 2006-11-02
US7309713B2 (en) 2007-12-18
CN101132793A (zh) 2008-02-27
BRPI0606897A2 (pt) 2009-07-21
TW200637548A (en) 2006-11-01
RU2007132725A (ru) 2009-03-10
EP1843765A2 (en) 2007-10-17
IL183557A0 (en) 2007-10-31
MX2007009187A (es) 2007-09-21

Similar Documents

Publication Publication Date Title
AR055723A1 (es) Uso del farmaco analgesico no opiaceo flupirtina para el tratamiento de vejiga hiperactiva y enfermedades asociadas, que incluyen incontinencia por urgencia, problemas de flujo urinario como consecuencia de hiperplasia de prostata y sindrome de intestino irritable
ES2557988T3 (es) Método para tratar enfermedades de próstata basado en el suministro local de principios activos
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
MX2010005629A (es) Preparacion farmaceutica para tratamiento de hiperplasia prostatica benigna.
BRPI0706676B8 (pt) uso de uma solução aquosa com potencial de oxirredução
AR061350A1 (es) Regimen extendido de reduccion progresiva de estrogenos
Huang et al. Effect of transurethral split of the prostate using a double-columnar balloon catheter for benign prostatic hyperplasia: A single-center experience of 565 consecutive patients
Bonamonte et al. Fusidic acid in skin infections and infected atopic eczema
MY164900A (en) Use of an alpha-adrenoceptor antagonist in combination with a muscarinic antagonist in the manufacture of a medicament for treating the lower urinary tract symptoms associated with benign prostatic hyperplasia
CL2008002984A1 (es) Composicion farmaceutica que comprende micofenolato sodico y su uso para el tratamiento y/o prevencion en enfermedades autoinmunes tales como el rechazo de aloinjertos o xenoinjertos de organos, celulas o tejidos y como antiinflamatorio.
ES2551690T3 (es) Método de tratamiento de la prostatitis crónica no bacteriana con moduladores selectivos del receptor de estrógeno o inhibidores de aromatasa
CL2008003201A1 (es) Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.
Strup-Perrot et al. Expression and activation of MMP-2,-3,-9,-14 are induced in rat colon after abdominal X-irradiation
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
AR081439A1 (es) Composicion para el tratamiento de la hiperplasia prostatica benigna de prostata
BRPI0406796A (pt) Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina
PA8578001A1 (es) Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
Zhang et al. [Retracted] Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non‐Muscle‐Invasive Bladder Cancer Recurrence
Verit et al. Fournier's gangrene: the development of a classical pathology
Park et al. Effects of clozapine on behavioral sensitization induced by cocaine
BRPI0517983A (pt) uso de corticosteróide em associação com diurético e antiácido para tratamento de estenose vascular e prevenção de reestenose vascular
Giuliano et al. Comparison between tamsulosin and alfuzosin on the expulsion phase of ejaculation in rats
BR112022026558A2 (pt) Novo composto e composição farmacêutica para prevenir ou tratar câncer resistente que compreende o mesmo
Perera et al. Sexual and urinary dysfunction following rectal dissection compared with segmental colectomy
Armitage et al. Is it time to reconsider the role of prostatic inflammation in the pathogenesis of lower urinary tract symptoms?

Legal Events

Date Code Title Description
FA Abandonment or withdrawal